---
aliases: [SNY]
---
#actor #pharma #vaccines #france #public

**Sanofi** — French pharma. Dupixent blockbuster. Vaccines. Consumer health spinoff.

---

## Why Sanofi matters

| Metric | Value |
|--------|-------|
| Ticker | SNY (ADR) |
| Market cap | ~$130B |
| Revenue | ~$45B |
| HQ | Paris, France |
| Key drug | **Dupixent** |

---

## Business segments

| Segment | Focus |
|---------|-------|
| **Biopharma** | Dupixent, immunology |
| **Vaccines** | Flu, pediatric |
| **Consumer Health** | Spinning off |

---

## Dupixent franchise

| Metric | Value |
|--------|-------|
| 2024 sales | ~$13B |
| Growth | Double-digit |
| Partner | Regeneron |
| Indications | Atopic dermatitis, asthma, COPD |

**Star asset:** Dupixent drives majority of growth.

---

## Key drugs

| Drug | Indication | Status |
|------|------------|--------|
| **Dupixent** | Immunology | Blockbuster |
| **Aubagio** | Multiple sclerosis | Mature |
| **Kevzara** | Rheumatoid arthritis | Growing |
| **Sarclisa** | Multiple myeloma | Growing |

---

## Vaccines business

| Vaccine | Target |
|---------|--------|
| Flu vaccines | Seasonal |
| Pediatric | DTP, polio |
| Travel | Various |
| COVID | Partnership |

---

## Consumer health spinoff

| Detail | Status |
|--------|--------|
| Plan | Separate listing |
| Brands | Allegra, Dulcolax |
| Focus | Pure-play pharma post-spin |

---

## Investment case

**Bull:**
- Dupixent $13B+ and growing
- Vaccines stable revenue
- Consumer spinoff catalyst
- Regeneron partnership
- Undervalued vs US peers

**Bear:**
- Dupixent concentration risk
- Vaccine commoditization
- Pipeline gaps
- European pharma discount
- Currency headwinds

---

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | SNY |
| Revenue | ~$45B |
| Key drug | Dupixent (~$13B) |
| Partner | Regeneron |

---

## Related

- [[Biopharma]] — sector
- [[Regeneron]] — Dupixent partner
- [[Novartis]] — European peer
- [[AstraZeneca]] — European peer

---

## Sources

- Company filings

*Created 2026-01-09*
